The Brussels International Declaration on Lipoprotein(a) Testing and Management

Atherosclerosis, Journal Year: 2025, Volume and Issue: unknown, P. 119218 - 119218

Published: May 1, 2025

There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %-2 %) despite the fact 1 in 5 individuals have elevated concentrations. The Brussels International Declaration on Testing Management was co-created by Task Force global leaders at Global Summit, held Brussels, Belgium, March 24-25, 2025. event, organized FH Europe Foundation, brought together scientific experts, people with lived experience of policy makers from European Institutions World Health Organization. Heart Federation, Hub, Alliance for Cardiovascular organizations such as Atherosclerosis Society, Society were formal partners. Summit hosted Member Parliament, Romana Jerković, under patronage Polish presidency Council Union. calls 1) integration management into Global, National Plans; 2) appropriate investment, programmes targeting based recent study demonstrating substantial overall cost-saving to health systems across globe; 3) political commitment mandate systematic least once during person's lifetime, ideally an early age, full reimbursement; 4) incorporation test results context assessment, development personalised roadmaps needed, without fear discrimination; 5) investment public healthcare professional education increase awareness its impact health.

Language: Английский

Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis

PharmacoEconomics, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 2, 2024

Language: Английский